期刊文献+

大肠埃希菌产超广谱β-内酰胺酶的监测及危险因素分析 被引量:20

Surveillance of ESBLs producing in Escherichia coli and analysis of risk factors
下载PDF
导出
摘要 目的调查医院大肠埃希菌感染的临床分布、耐药性及患者感染产超广谱β-内酰胺酶(ESBLs)菌的危险因素,为临床合理使用抗菌药物提供科学依据。方法采用法国生物梅里埃公司ATB细菌鉴定仪对产ES-BLs菌进行检测,药敏试验用K-B纸片法,根据2005年美国临床实验室标准化委员会标准判断结果,应用WHO-NET5软件对临床分离细菌的药敏结果进行数据统计分析。结果确证87株产ESBLs菌,产酶率为31.5%;不同标本种类中产ESBLs菌检出情况分别为尿液35株(40.2%),痰液23株(26.4%),血液7株(8.0%);各病区产ES-BLs菌的分离率以重症监护病房(ICU)最高(47.1%),其次为烧伤病房(40.0%),泌尿外科病房(34.2%);产ES-BLs大肠埃希菌的耐药率明显高于非产ESBLs大肠埃希菌;感染产ESBLs菌危险因素为长期使用三代头孢菌素、入住ICU患者。结论该院大肠埃希菌产ESBLs菌尚未有效控制,仍然处于较高水平;治疗大肠埃希菌感染时,需根据药敏结果及患者病情选用碳青霉烯类、氨基糖苷类、β-内酰胺类抗生素/β-内酰胺酶抑制剂等。 Objective To investigate the clinical distribution,drug resistance and risk factor of Escherichia coli(E.coli) infection so as to provide the scientific basis for reasonable clinical use of antibacterials.Methods To detect ESBLs-producing bacteria by ATB microbiological system.The Kirby-Bauer(K-B) test was adopted for the drug susceptibility test.The results were evaluated based on the National Committee for Clinical Laboratory Standards(NCCLS) of USA in 2005.The data were analyzed by using WHONET-5 software.Results 87 strains of ESBLs-producing bacteria were detected and the isolated rate was 31.5%.Among different samples,35 strains(40.2%) of ESBLs-producing bacteria were isolated from urine samples,23 strains(26.4%) from sputum,and 7 strains(8.0%) from blood.The isolated rate of ESBLs-producing bacteria was highest in ICU(47.1%),the second was in the burn wards(40.0%) and the urology wards(34.2%).The resistant rates of ESBLs-producing strains were significantly higher than that non ESBLs-producing E.coli.The risk factors for infection of ESBLs-producing bacteria were the long-period use of the third-generation of cephalosporins and admission to ICU.Conclusion ESBLs-producing E.coli isolated in our hospital have not been effectively controlled and are still in high level.In treating E.coli infection,carbopenems,aminoglycosides,β-lactam/β-lactamase inhibitor should be selected according to the results of drug sensitivity tests and disease condition.
出处 《检验医学与临床》 CAS 2012年第19期2403-2404,2406,共3页 Laboratory Medicine and Clinic
关键词 产超广谱Β-内酰胺酶 大肠埃希菌 耐药 危险因素 ESBLs-producing Escherichia coli drug resistance risk factors
  • 相关文献

参考文献8

二级参考文献44

  • 1金少鸿.抗生素在食用动物中的应用以及食源性疾病对人类健康的影响[J].中华微生物学和免疫学杂志,2001,21(S1):25-25. 被引量:8
  • 2李立津,官兰.氟喹诺酮等抗菌药物体外抗菌活性及其临床意义[J].中华内科杂志,1993,32(3):148-151. 被引量:1
  • 3郭文学,官兰,吴瑾,刘德孟,宋诗铎,胡文芝.五种氟喹诺酮类药物对临床分离致病菌的体外抗菌活性[J].天津医药,1996,24(10):611-613. 被引量:1
  • 4[5]Bush K,Jscky GA,Medeiros A.A functional classification scheme for β-lactamase and its correlation with molecular structure[J].Antimicrob Agents Chemother,1995,39(6): 1211.
  • 5Clifford ML, Feng JC, Hsiu JL, et al. Emergence of reduced susceptibility and resistance to fluoroquinolones in Escherichia coli in Taiwan and contributions of distince selective pressures[J]. Antimicrob Agents Chemother, 2001, 45: 3084-3091.
  • 6Bingen EH, Desjardins P, Arlet G,et al. Molecular epidemiology of plasmid spread among extended broad-spectrum-β-lac-tamase-producing Klebsiella pneumoniae isolates in a pediatric hospital[J]. J Clin Microbiol, 1993, 31: 179.
  • 7National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial disk susceptibility tests approved standard [S]. Seventh edition. NCCLS M100-S10(M7), January 2000.
  • 8Patterson JE, Hardin TC, Kelly CA, et al. Association of antibiotic utilization measures and control of multiple-drug resistance in Klebsiella pneumoniae[J]. Infect Control Hosp Epidemiol, 2000, 21: 455-458.
  • 9Schiappa DA, Hayden MK, Matushek MG, et al. Cef-tazidime-resistant Klebsiella pneumoniae and Escherichia coli blood stream infection: a case-control and molecular epidemiologic investigation[J]. J Infect Dis, 1996, 174: 529-536.
  • 10Rahal JJ, Urban C, Segal-Manrer S. Nosocomial antibiotic resistance in multiple Gram-negative species : experience at one hospital with squeezing the resistance balloon at multiple sites[J]. CID, 2002, 34: 499-503.

共引文献270

同被引文献137

引证文献20

二级引证文献82

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部